These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 30670815)

  • 1. Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
    Wang JJ; Zou JX; Wang H; Duan ZJ; Wang HB; Chen P; Liu PQ; Xu JZ; Chen HW
    Acta Pharmacol Sin; 2019 Aug; 40(8):1067-1075. PubMed ID: 30670815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
    Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
    Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
    Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
    Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.
    Zhu L; Yu CL; Zheng Y
    Biochem Biophys Res Commun; 2019 Nov; 519(3):489-496. PubMed ID: 31526565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
    He C; Liu C; Wang L; Sun Y; Jiang Y; Hao Y
    Cell Death Dis; 2019 Jan; 10(2):65. PubMed ID: 30683853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
    Ding L; Xie Z
    Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer.
    Zhao LH; Li Q; Huang ZJ; Sun MX; Lu JJ; Zhang XH; Li G; Wu F
    Cell Death Dis; 2021 Oct; 12(11):974. PubMed ID: 34671018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
    Das SG; Romagnoli M; Mineva ND; Barillé-Nion S; Jézéquel P; Campone M; Sonenshein GE
    Breast Cancer Res; 2016 Apr; 18(1):40. PubMed ID: 27039296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
    Wang Q; Zheng J; Zou JX; Xu J; Han F; Xiang S; Liu P; Chen HW; Wang J
    Chem Biol Interact; 2020 Feb; 317():108965. PubMed ID: 32001260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCAP31 drives TNBC development by modulating ligand-independent EGFR trafficking and spontaneous EGFR phosphorylation.
    Fu W; Sun H; Zhao Y; Chen M; Yang X; Liu Y; Jin W
    Theranostics; 2019; 9(22):6468-6484. PubMed ID: 31588230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
    Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
    Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer.
    Shao Z; Ma X; Zhang Y; Sun Y; Lv W; He K; Xia R; Wang P; Gao X
    Mol Carcinog; 2020 May; 59(5):533-544. PubMed ID: 32181526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
    Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
    Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
    Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
    Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sophoraflavanone G suppresses the progression of triple-negative breast cancer via the inactivation of EGFR-PI3K-AKT signaling.
    Cheng W; Liu D; Guo M; Li H; Wang Q
    Drug Dev Res; 2022 Aug; 83(5):1138-1151. PubMed ID: 35426453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
    Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
    J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.